Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TOP2A | P11388 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.54 |
| ▸ | TOP1 | P11387 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569671 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL9181336 | 0.88 | KDM4E (0.61) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL8565928 | 0.87 | KDM4E (0.60) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL8565922 | 0.87 | KDM4E (0.60) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL5566797 | 0.86 | KDM4E (0.69) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL2183935 | 0.86 | KDM4E (0.60) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL8924287 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL8924380 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL8925813 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL8923552 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104922-A2 | LECTIN-TARGETING CONJUGATES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-06-15 | — | — | WO | disclosed |
| EP-1730154-B1 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE IP VENTURES L P (US) | 2012-10-17 | — | — | EP | disclosed |
| US-7247634-B2 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1730154-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005070940-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | RIF1, MRPL37, AURKAIP1 | KDM4E 2995/4885ALDH1A1 1731/4885LMNA 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.